PolyPid adds PD01B for moderate to severe diabetic foot infections to pipeline

What PolyPid announced

PolyPid unveiled PD01B on 28 October at a virtual Investor Day, calling it the first step in extending its Kynatrix technology from preventing infections to treating them. The candidate is designed to deliver doxycycline locally after wound debridement, the company said. It will be developed as a new drug application.

PD01B targets moderate to severe diabetic foot infections. PolyPid said the condition is among the most serious and costly complications of diabetes, which affects an estimated 589 million adults worldwide. Between one in five and one in three people with diabetes will develop a foot ulcer in their lifetime, and about half of those ulcers are already infected when patients present for care, the company said.

The stakes are concrete. Diabetic foot infections are the most frequent diabetes-related complication requiring hospitalization and the most common event leading to lower-extremity amputation, according to PolyPid. In one large prospective study cited in 2023 international guidelines, one year after presenting with an infected foot ulcer only 46% of patients had healed, 17% had undergone a lower-extremity amputation and 15% had died.

Why PolyPid says it can move faster

PD01B is a distinct product with its own formulation, indication and care setting, CEO Dikla Czaczkes Akselbrad said. But it is built on the Kynatrix technology that was clinically validated in the Phase 3 SHIELD II trial of D-PLEX100, and it uses PolyPid's established manufacturing capabilities. The company argues that gives PD01B a potentially accelerated, more capital-efficient path into the clinic.

The D-PLEX100 programme is further along. It is under FDA review for the prevention of surgical site infections in abdominal colorectal surgery.

The D-PLEX100 backdrop

PolyPid is positioning PD01B as the next step for a company that is close to its first regulatory decision. D-PLEX100 is under FDA Priority Review, and the FDA reported no filing review issues, PolyPid said. The company has a US and Canada commercialization deal with Azurity Pharmaceuticals signed on 17 July 2026. Acceptance of the D-PLEX100 application triggered a $15 million Azurity milestone, completing $30 million in upfront and near-term payments.

Financially, PolyPid remains loss-making. Yahoo Finance data cited by ad-hoc-news showed a net loss of $7.85 million and diluted EPS of negative $0.35 for the half year ended 30 June 2026. TipRanks reported that the company narrowed net losses for both the three- and six-month periods ended 30 June 2026 as research spending shifted from late-stage clinical trials to regulatory and commercial readiness. PolyPid's market capitalization was $94.5 million on 7 October 2026, according to ad-hoc-news. The $30 million already delivered under the Azurity deal is nearly four times the half-year net loss, and TipRanks reported the partnership includes funding for additional clinical development to seek broader surgical site infection indications.

What happens next

D-PLEX100 has a Prescription Drug User Fee Act (PDUFA) goal date of 28 November 2026. PolyPid expects a US launch in early 2027, subject to approval. For PD01B, the pre-IND meeting and first-in-human study are both planned for the second half of 2027.

PD01B is at an early stage. The announcement gives PolyPid a second asset to discuss with investors and partners as it approaches the D-PLEX100 decision, and it tests whether Kynatrix can work as a treatment as well as a preventive.